Candel Therapeutics Unveils Promising Phase 3 Trial Results

An update from Candel Therapeutics ( (CADL) ) is now available.

On May 22, 2025, Candel Therapeutics announced that their phase 3 clinical trial results for CAN-2409 in intermediate-to-high-risk localized prostate cancer will be presented at the 2025 ASCO Annual Meeting. The trial, which met its primary and secondary endpoints, showed a statistically significant improvement in disease-free survival, reducing the risk of prostate cancer recurrence or death by 30%. This marks the first successful multicenter, randomized phase 3 trial in over 20 years for localized prostate cancer, potentially redefining treatment for these patients. The results, initially announced in December 2024, highlight CAN-2409’s promise as an innovative immunotherapy with a favorable safety profile.

The most recent analyst rating on (CADL) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Candel Therapeutics stock, see the CADL Stock Forecast page.

Spark’s Take on CADL Stock

According to Spark, TipRanks’ AI Analyst, CADL is a Underperform.

Candel Therapeutics is currently facing substantial financial challenges with no revenue and ongoing cash burn, which heavily weighs down its stock score. Despite positive clinical trial results offering future potential, the current technical and valuation metrics remain unfavorable, reflecting the speculative nature of the stock.

To see Spark’s full report on CADL stock, click here.

More about Candel Therapeutics

Candel Therapeutics is a clinical stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies to elicit individualized, systemic anti-tumor immune responses. The company has established platforms based on genetically modified adenovirus and HSV gene constructs, with CAN-2409 being its lead product candidate from the adenovirus platform.

Average Trading Volume: 1,036,301

Technical Sentiment Signal: Sell

Current Market Cap: $296.1M

Learn more about CADL stock on TipRanks’ Stock Analysis page.